A Multi-center, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease

Trial Profile

A Multi-center, Double-blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients With Parkinson's Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2017

At a glance

  • Drugs Droxidopa (Primary)
  • Indications Orthostatic hypotension; Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Chelsea Therapeutics
  • Most Recent Events

    • 20 May 2017 Results (n=120) assessing the imapct of droxidopa on fear of falling in patients with Parkinson disease and symptomatic nOH, presented at the 2017 Annual Scientific Meeting of the American Geriatrics Society.
    • 06 Jan 2017 Results (n=907) assessing CV safety of Droxidopa using patient data from NOH-301, NOH-302, NOH-303, NOH-304 and NOH-306 trials published in the American Journal of Cardiology.
    • 12 Jun 2016 Results assessing comparison of the rate of patient-reported falls (n = 197) published in the Clinical Neuropharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top